Navigation Links
Risks Associated With Face Transplants May Be Lower Than Previously Thought, ASPS Journal Review Suggests
Date:10/10/2007

ARLINGTON HEIGHTS, Ill., Oct. 10 /PRNewswire-USNewswire/ -- Face transplants, once on the fringe of medicine, may eventually become more mainstream because of new estimates that suggest the risk of tissue rejection might be lower than previously thought, according to a recent review in Plastic and Reconstructive Surgery(R) (PRS), the official medical journal of the American Society of Plastic Surgeons (ASPS).

"We can only know the true immunological risks associated with face transplants by carefully observing those who have already had the procedure," said ASPS President Roxanne Guy, MD. "While this paper doesn't provide conclusive evidence of the immunological risks, it will help us move forward in making face transplants part of mainstream medicine."

Currently, immunosuppressive drugs are the biggest barrier the medical community faces in performing any transplant because the potential long-term side effects of these medications can make the risk too great.

The authors suggest previous immunological risk projections are inaccurate because they were based on immunosuppression drug regimes that are different than the regimes that will be required of face transplant patients.

When utilizing an immunosuppressive drug regimen consistent with face transplant recipient requirements, the authors believe patients would have a relatively low risk of chronic or continual rejection after surgery -- less than 10 percent. In addition, advances in immunosuppression therapies have increased the capacity to manage face transplant patients and potentially reduce acute or immediate rejection episodes.

The authors also suggest that the immunological risks are lower because face transplant patients may on average be healthier and less likely to suffer from extenuating health issues. Organ transplant recipients, on the other hand, often are extremely sick and have numerous, pre-existing health conditions that make them more susceptible to the complications related to immunosuppressive treatment. For example, kidney transplant recipients commonly have hypertension, diabetes, anemia or bone disease. Face transplant recipients; however, may not be hindered by additional health concerns, lowering their risk.

Additionally, the human hand is comprised of similar tissue as the face. This has led plastic surgeons to hypothesize that face transplant patients would carry similar low risk of acute rejection as hand transplant recipients.

Visit http://www.plasticsurgery.org for referrals to ASPS Member Surgeons and to learn more about cosmetic and reconstructive plastic surgery.

The American Society of Plastic Surgeons is the largest organization of board-certified plastic surgeons in the world. With more than 6,000 members, the society is recognized as a leading authority and information source on cosmetic and reconstructive plastic surgery. ASPS comprises 90 percent of all board-certified plastic surgeons in the United States. Founded in 1931, the Society represents physicians certified by The American Board of Plastic Surgery or The Royal College of Physicians and Surgeons of Canada.


'/>"/>
SOURCE American Society of Plastic Surgeons
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Controlling the Spread of Healthcare Associated Methicillin Resistant Staphylococcus aureus Requires Active Surveillance
2. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
3. Byetta Treatment for Three and a Half Years Associated with Reductions in Cardiovascular Risk Factors in People with Type 2 Diabetes
4. Neurogen Proprietary Insomnia Compound Data for Two Studies Presented at Associated Professional Sleep Societies Annual Meeting
5. Neurogen Proprietary Insomnia Compound Data Presented at Associated Professional Sleep Societies Annual Meeting
6. NCI Researchers Discover Genes That Are Turned on at High Levels in Tumor-associated Blood Vessels of Mice and Humans
7. Vanda Pharmaceuticals To Present Data on VEC-162 at SLEEP 2007, the Annual Meeting of the Associated Professional Sleep Societies
8. Pooled Studies Showed Desvenlafaxine Succinate Significantly Improved Painful Symptoms and Anxious Symptoms Associated with Major Depressive Disorder in Adults, Compared With Placebo
9. Clinical Trial Results Suggest Long-Term Treatment Benefit of Tetrabenazine for Chorea Associated with Huntingtons Disease
10. Cephalon Presents Positive Results for Fentora in Breakthrough Pain Associated with Neuropathic Conditions
11. Insmed Releases Positive Results from Iplex Phase II HIV-Associated Adipose Redistribution Syndrome Clinical Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/25/2017)... PROVIDENCE, R.I. , Sept. 25, 2017 /PRNewswire/ ... immunogenicity assessment, vaccine design, and immune-engineering today announced ... focused on the development of personalized therapeutic cancer ... and has provided exclusive access to enabling technologies ... MSc Eng., MBA will lead EpiVax Oncology as ...
(Date:9/19/2017)... Ky. , Sept. 19, 2017   ZirMed Inc ... predictive analytics, today announced that it has been ranked #1 ... Black Book™ Rankings 2017 User Survey. ZirMed was ... solution for large hospitals and medical centers over 200 beds ... Black Book,s healthcare technology user survey history. ...
(Date:9/12/2017)... MOUNTAIN LAKES, N.J. , Sept. 12, 2017  Consumer reviews ... Embrace Hearing as the number one company for hearing ... Oticon™, ReSound™ and fifteen other brands. ... Embrace Hearing Named #1 by Consumers For Hearing Aids ... Embrace Hearing is an online store that ...
Breaking Medicine Technology:
(Date:10/12/2017)... ... 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ), one of the ... new design of the shoulder pad. The shoulder pad provides optimal support and ... pain while using cold therapy. By utilizing ice and water that is circulated from ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... a leader in post-acute health care, have expanded their existing home health joint ... Health. , AccentCare has been operating a joint venture home health company with ...
(Date:10/12/2017)... ... 2017 , ... Dr. Parsa Mohebi, the Los Angeles based ... the newly revamped Cosmetic Town journal section, featuring articles written by ... as Follicular Unit Extraction (FUE). , Dr. Mohebi says “I enjoy ...
(Date:10/12/2017)... Washington, D.C. (PRWEB) , ... October 12, 2017 , ... ... of their peers in Washington, D.C., for the 49th Congress of the International ... Ph.D ., Vice President of the Center for Cancer and Blood Disorders ...
(Date:10/12/2017)... ... October 12, 2017 , ... Women-owned and Grand Rapids-based workplace ... Brightest in Wellness® by Best and Brightest. OnSite Wellness will be honored at ... from 7:30 a.m. to 2 p.m. at the Henry Autograph Collection Hotel, located ...
Breaking Medicine News(10 mins):